logo-loader
CytoDyn

CytoDyn to meet with FDA to finalize next steps on leronlimab drug trial for HIV

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors the FDA has requested an in-person meeting to discuss and potentially finalize the biotechnology company’s protocol for a trial of flagship drug leronlimab as a single treatment for HIV patients.

Dr Pourhassan also addresses the company's stagnant share price, and whether this poses a risk.

Quick facts: CytoDyn

Price: $0.38

Market: OTCQB
Market Cap: $141.32 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story

Watch

hVIVO PLC's 2020 pipeline 'looking strong' as it expands service offerings

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

9 hours, 42 minutes ago

2 min read

;